Virpax Pharmaceuticals, Inc.
VRPXDelisted Jul 21, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001708331
Virpax Pharmaceuticals, Inc. was delisted on Jul 21, 2025; its insiders filed their last Form 4 on Jul 10, 2024; 7 institutions reported holding it in 13F filings for Q1 2025, worth $34.9K in total; no superinvestor held it.
13F holders, Q2 2022
Institutional positions in Virpax Pharmaceuticals, Inc. as of Jun 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 16
- 0 vs. Q1 2022
- Shares held
- 1.87M
- −620.1K (−24.9%) vs. Q1 2022
- Total value
- $3.13M
- −$153.0K (−4.7%) vs. Q1 2022
- New holders
- 3
- 6 more added
- Sold out
- 3
- 2 more reduced
Compare with Q1 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting VRPX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 1 | $2 |
| Q1 2025 | 7 | $34.9K |
| Q4 2024 | 12 | $46.7K |
| Q3 2024 | 9 | $66.8K |
| Q2 2024 | 8 | $12.6K |
| Q1 2024 | 6 | $6.44K |
| Q4 2023 | 18 | $120.5K |
| Q3 2023 | 13 | $493.4K |
| Q2 2023 | 14 | $827.7K |
| Q1 2023 | 17 | $873.8K |
| Q4 2022 | 21 | $973.0K |
| Q3 2022 | 16 | $2.17M |
| Q2 2022 | 16 | $3.13M |
| Q1 2022 | 16 | $3.29M |
| Q4 2021 | 18 | $7.67M |
| Q3 2021 | 13 | $11.4M |
| Q2 2021 | 7 | $1.12M |
| Q1 2021 | 5 | $1.29M |
Institutions, Q2 2022
Shares, value and share of portfolio for each institution holding Virpax Pharmaceuticals, Inc.; share changes are against Q1 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Wells Fargo & Company | 57 | $0 | 0.00% | +4+7.5% | Added |
| Hantz Financial Services, Inc. | 100 | $0 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 160 | $0 | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 464 | $1.00K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 2,602 | $4.00K | 0.00% | +2,602 | New |
| Quantum Private Wealth, LLC | 10,000 | $16.0K | 0.01% | +10,000 | New |
| Citadel Advisors LLC | 11,380 | $19.0K | 0.00% | +11,380 | New |
| Northern Trust Corp | 15,221 | $26.0K | 0.00% | 00.0% | Unchanged |
| Cambridge Investment Research Advisors, Inc. | 16,820 | $28.0K | 0.00% | −350−2.0% | Reduced |
| Morgan Stanley | 18,016 | $30.0K | 0.00% | −60,495−77.1% | Reduced |
| Warberg Asset Management LLC | 19,500 | $33.0K | 0.01% | +1,790+10.1% | Added |
| Geode Capital Management, LLC | 66,223 | $111.0K | 0.00% | +3,210+5.1% | Added |
| The PNC Financial Services Group, Inc. | 100,875 | $169.0K | 0.00% | +75,750+301.5% | Added |
| Renaissance Technologies LLC | 203,200 | $341.0K | 0.00% | +46,600+29.8% | Added |
| Vanguard Group Inc | 341,977 | $575.0K | 0.00% | 00.0% | Unchanged |
| Sabby Management, LLC | 1,059,383 | $1.78M | 3.30% | +54,227+5.4% | Added |
| Kepos Capital LP | 0 | $0 | 0.00% | −750,000−100.0% | Sold out |
| Citigroup Inc | 0 | $0 | 0.00% | −12,179−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −2,689−100.0% | Sold out |